Dynavax Technologies Corp (DVAX)
11.17
-0.25
(-2.19%)
USD |
NASDAQ |
Apr 25, 16:00
11.16
0.00 (0.00%)
After-Hours: 20:00
Dynavax Technologies Accounts Receivable (Quarterly): 40.61M for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 40.61M |
September 30, 2023 | 46.35M |
June 30, 2023 | 43.24M |
March 31, 2023 | 101.74M |
December 31, 2022 | 145.13M |
September 30, 2022 | 129.77M |
June 30, 2022 | 172.27M |
March 31, 2022 | 133.97M |
December 31, 2021 | 116.22M |
September 30, 2021 | 200.36M |
June 30, 2021 | 105.90M |
March 31, 2021 | 83.99M |
December 31, 2020 | 22.30M |
September 30, 2020 | 35.02M |
June 30, 2020 | 0.903M |
March 31, 2020 | 8.135M |
December 31, 2019 | 8.886M |
September 30, 2019 | 8.822M |
June 30, 2019 | 7.582M |
March 31, 2019 | 5.791M |
December 31, 2018 | 3.704M |
September 30, 2018 | 1.507M |
June 30, 2018 | 1.304M |
March 31, 2018 | 0.763M |
December 31, 2017 | 0.854M |
Date | Value |
---|---|
September 30, 2017 | 0.783M |
June 30, 2017 | 0.81M |
March 31, 2017 | 1.465M |
December 31, 2016 | 1.342M |
September 30, 2016 | 2.29M |
June 30, 2016 | 1.864M |
March 31, 2016 | 1.164M |
December 31, 2015 | 1.394M |
September 30, 2015 | 1.163M |
June 30, 2015 | 0.657M |
March 31, 2015 | 0.909M |
December 31, 2014 | 0.727M |
September 30, 2014 | 0.727M |
June 30, 2014 | 1.292M |
March 31, 2014 | 1.73M |
December 31, 2013 | 1.627M |
September 30, 2013 | 2.159M |
June 30, 2013 | 2.025M |
March 31, 2013 | 1.547M |
December 31, 2012 | 1.005M |
September 30, 2012 | 3.685M |
June 30, 2012 | 1.284M |
March 31, 2012 | 1.375M |
December 31, 2011 | 9.527M |
September 30, 2011 | 0.783M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
0.903M
Minimum
Jun 2020
200.36M
Maximum
Sep 2021
74.27M
Average
46.35M
Median
Sep 2023
Accounts Receivable (Quarterly) Benchmarks
Supernus Pharmaceuticals Inc | 144.16M |
Ligand Pharmaceuticals Inc | 32.92M |
Pacira BioSciences Inc | 105.56M |
Esperion Therapeutics Inc | 48.49M |
PetIQ Inc | 126.84M |